Logo
  • About
    • What We Do
    • Team
    • Partners
  • Pipeline
  • Technologies
    • FastPharming®
    • Glycaneering™
    • LicKM
    • VLP
  • Resources
    • News
    • Events
    • Articles
    • Publications
  • Careers
  • Investors
  • Contact
  • Therapeutics
    • Fibrosis
      • IBIO-100
  • Vaccines
    • Covid-19
      • IBIO-201 Subunit Vaccine
    • Classic Swine Fever
      • IBIO-400
  • Research & Bioprocess
  • CDMO Services
    • Process Development
    • cGMP Manufacturing
    • Aseptic Fill/Finish
    • Bioanalytics
    • Factory Solutions
Investors

Press Releases

Investors

Investors

  • Overview
  • Company Info
    • Profile
    • Management Team
    • Presentations
  • News & Events
    • Press Releases
    • IR Calendar
  • Stock Data
    • Quote
    • Historical Data
  • SEC Filings
  • Corporate Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Resources
    • IR Contact
    • Email Alerts
    • Investor FAQ
  • News & Events

  • Press Releases
  • IR Calendar
Sep 09, 2020 8:45am EDT

iBio to Advance COVID-19 LicKM-Subunit Vaccine Candidate, IBIO-201

Aug 28, 2020 7:15am EDT

iBio and Planet Biotechnology Enter into Exclusive Worldwide License Agreement for the Development of a COVID-19 Therapeutic

Aug 10, 2020 7:15am EDT

iBio Provides Update on IBIO-201 COVID-19 Vaccine Program

Jun 26, 2020 6:45am EDT

iBio to be Added to the Russell 2000® and Russell 3000® Indexes

Jun 24, 2020 6:45am EDT

iBio Selected by IBM Watson Health for the use of IBM Clinical Development Solution at No Cost to help Support clinical COVID-19 Vaccine Candidates

Jun 04, 2020 7:00am EDT

iBio Announces Second COVID-19 Vaccine Program

Apr 27, 2020 4:15pm EDT

iBio Estimates ~500 Million Dose Capacity for COVID-19 Vaccine from its FastPharming Facility™

Apr 09, 2020 7:30am EDT

iBio Expands COVID-19 Vaccine Collaboration to Include the Infectious Disease Research Institute

Mar 26, 2020 4:20pm EDT

iBio Supporting AzarGen Biotechnologies’ Development of a Rituximab Biosimilar

Mar 26, 2020 7:30am EDT

iBio Announces Advancement of COVID-19 Vaccine Program

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …11
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Footer Logo
  • Therapeutics
    • Fibrosis
      • IBIO-100
  • Vaccines
    • Covid-19
      • IBIO-201 Subunit Vaccine
    • Classic Swine Fever
      • IBIO-400
  • Research & Bioprocess
  • CDMO Services
    • Process Development
    • cGMP Manufacturing
    • Aseptic Fill/Finish
    • Bioanalytics
    • Factory Solutions

iBio, Inc.
iBio CDMO, LLC

8800 HSC Pkwy
Bryan, TX 77807

(979) 446-0027
LinkedIn
info@ibioinc.com
RSS News Feed

© 2021 iBio. All Rights Reserved.
Privacy Policy

  • About
  • Pipeline
  • Technologies
  • Resources
  • Careers
  • Investors
  • Contact